# Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)

> **NCT03493581** · NA · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 450 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Patients

## Interventions

- **PROCEDURE:** BIOPSY
- **DIAGNOSTIC_TEST:** blood-sampled
- **OTHER:** feces samples

## Key facts

- **NCT ID:** NCT03493581
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-08
- **Primary completion:** 2024-03-08
- **Final completion:** 2024-08-12
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493581, "Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03493581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*